VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Vir Biotechnology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Market Cap | $1.73B | $197.05M |
| Enterprise Value | $1.20B | $106.56M |
| PS Ratio | 5.70 | 3.93 |
| PB Ratio | 1.76 | 2.14 |
| P/TBV Ratio | 1.80 | 2.46 |
Enterprise value
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| EV / Sales | 3.95 | 2.69 |
Income (trailing twelve months)
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Revenue | $303.23M | $57.94M |
| Operating Income | -$280.19M | -$21.44M |
| Pretax Income | -$251.30M | -$14.45M |
| Net Income | -$251.68M | -$22.46M |
| EBITDA | -$268.68M | -$16.91M |
| EPS (Diluted) | -$1.86 | -$0.83 |
Margins
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Operating Margin | -92.4% | -44.5% |
| Pretax Margin | -82.9% | -13.0% |
| Profit Margin | -83.0% | -39.2% |
| EBITDA Margin | -88.6% | -31.3% |
| FCF Margin | -67.1% | -8.85% |
Returns
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.1% | -53.1% |
| Return on Assets (ROA) | -20.9% | -41.0% |
| Return on Invested Capital (ROIC) | -55.2% | -32.0% |
| Return on Capital Employed (ROCE) | -25.0% | -37.8% |
Growth
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1495.9% | 6.01% |
| Revenue Growth (3Y CAGR) | -65.1% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.14% | 6.42% |
Balance sheet
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $528.59M | $62.42M |
| Net Cash (Debt) | $528.59M | $15.68M |
| Net Cash Per Share | $3.12 | $0.65 |
| Equity (Book Value) | $982.49M | $48.79M |
| Book Value Per Share | $5.81 | $1.36 |
| Tangible Book Value | $957.85M | $23.06M |
| Working Capital | $478.78M | $75.77M |
Financial position
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Current Ratio | 6.04 | 3.30 |
| Quick Ratio | 5.57 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Operating Cash Flow | -$202.51M | -$12.35M |
| Capital Expenditures | -$1.09M | -$1.06M |
| Free Cash Flow | -$203.59M | -$20.28M |
| FCF Per Share | -$1.20 | -$0.41 |
Efficiency
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Asset Turnover | 0.25 | 0.38 |
| Revenue Per Employee | $826.23K | $398.96K |
| Profits Per Employee | -$685.77K | -$732.08K |
| Employee Count | 367 | 73 |
Dividends and yields
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Earnings Yield | -14.6% | -21.2% |
| FCF Yield | -11.8% | -7.64% |
Shares
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Shares Outstanding | 169,216,000 | 59,128,900 |
| Shares Change (YoY) | 8.19% | 11.1% |
| Shares Change (QoQ) | 4.93% | 0.54% |
| Float | 139,448,000 | 48,744,500 |
| Shares Held by Insiders | 17.6% | 11.8% |
| Shares Held by Institutions | 86.6% | 59.4% |
Taxes
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Income Tax | $380.00K | $91.50K |
Scores
| Measure | Vir Biotechnology | Industry median |
|---|---|---|
| Altman Z-Score | 2.99 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Vir Biotechnology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.